Inhibition of blood coagulation factors by serine esterase inhibitors  by De Lange, J.A. & Hemker, H.C.
Volume 24, number 3 FEBS LETTERS August 1972 
1. Introduction 
INHIBITION OF BLOOD COAGULATION FACTORS BY 
SERINE ESTERASE INHIBITORS 
J.A. DE LANGE and H.C. HEMKER 
Laborator>> of Pathological Biochemistry II, 
University Hospital, Leiden, The Netherlands 
Received 14 June 1972 
The reaction mechanism of blood coagulation 
presumably comprises a series of proenzyme-en- 
zyme conversions. In a strict sense this has only 
been proven for prothrombin (factor II) which has 
been shown upon activation to yield the serine 
esterase thrombin [I]. 
The coagulation factors II, VII, IX and X have 
much in common, both in the way of synthesis 
(dependence upon vitamin K) and physicochemical 
properties [2]. It therefore is conceivable that these 
four factors are proenzymes of serine esterases, that 
is they are serine esterases when in their activated 
forms*. 
It has been shown that factor X, can split organ- 
ic esters and is inhibited by DFP [3]. No enzyma- 
tic properties have been found to the factors V, 
and VIII, [ 18, 191. We set out to investigate the 
inhibitory action of a set of 25 known serine ester- 
ase inhibitors on the activities of coagulation factors 
II, V, VII, VIII, IX and X with the purpose of find- 
ing out which af these were serine esterases. We also 
hoped to find specific inhibitors for each factor 
which would greatly facilitate further research in 
blood coagulation. 
* The active form will be indicated by the subscript a, so 
factor II, = thrombin etc. 
2. Materials and methods 
2.1. Serine esterme inhibitors 
The serine esterase in~bitors were chosen from 
those described by Myers and coworkers [4,5]. As 
the material had been stored for 15 years, their 
ability to inhibit rat brain aliesterase was tested 
(according to [6] ) and compared to the original 
activity as given by Myers et al. [4, 51. Of the 78 
i~ibitors 52 had kept their original activity. 2-N02- 
~carboxyphenyl-~-~-diphenylcarbamate (NCDC) 
was prepared according to Erlanger [a] in the labo- 
ratory for organic chemistry (Head, Prof. Dr. E. Ha- 
vinga) in Leiden. 
2.2. Coagulation factor assays and prepara tiuns 
Activities of factors II, VII, V and X and throm- 
bin were determined in one+tage assays as de- 
scribed in [ 131 . Factor VIII and IX activities were 
estimated as described by Veltkamp et al. [9], and 
factor X, was determined by mixing 0.1 ml sample, 
0.1 ml Seitz filtered oxalated bovine plasma (de- 
ficient in factors VII and X) and 0.1 ml phospho- 
lipid suspension. After 30 see 0.1 ml 25 mM CaC12 
was added and the clotting time was measured. Fac- 
tor VII, was tested like factor VII, but with the 
use of bovine brain thromboplastin instead of human 
material. Due to the species specificity of the factor 
VII-activating enzyme in the thrombopiastin, this 
test only measures human material that has been 
activated, i.e. VII,. Factor VII,, X, and IX, prep- 
arations were obtained by purification from human 
serum according to the procedures described by 
North-Roland Publishing Company - Amsterdam 
Volume 24, number 3 FEBS LETTERS August 1972 
Table 1 
NO. structure Molar 
concentration 
‘Ia 
Inhibition (%) of factor 
VII, 
1 
2 
3 
4 
6 
7 
8 
9 
10 
11 
12 
pCl-Ph-O-C(= O)-NH-Me 
Ph-O-C(= O)-NH-Me 
Ph-0-C(= O)-NH-Et 
Ph-0-C(= O)-NH-Pr 
pfl-Ph-0-C(= O)-NH-Ph 
pMe-Ph-0X(= O)-NH-Me 
oNOz-Ph-OC(= O)-N-Me2 
oMe,-N-Ph-0-C(= O)-NH-Me 
~NH~-Ph-~C(= O)-N(CH& 
mNOz-Ph-0-C(= 0)-N(CH3)2 
m(MezCH(CHJ)). Ph-OC(= 0) NHCH3 
Ph2-N-C(= O)-0-Ph-oNO*~COOH 
13 
14 
KNOT-Ph-O)*-P(= OtPh 
@NOz-Ph-0)2-P(= 0)Cyc. hex. 
15 @N02-Ph-0)2-P(= O)-lsoprop. 
16 
17 
18 
19 
20 
(pNOz-Ph-O)z-P(= O)-eth. 
@NOz-Ph-0)2-P(= O)CHz-Phe 
KNOT-Ph-0)2-P(= 0)-O-Ph 
(pNOz-Ph-0)2-P(= O)-NH-Me 
(Cl-Ph-0)2-P(= O)-NH2 
21 
22 
23 
24 
25 
(Cl-Ph-0)2-P(= O)_NH-Me 
(Cl-Ph-0)2-P(= O)-NMe2 
@NOz-Ph-O)z-P(= O>NH-Phe 
@NOz-Ph-0)2-P(= O)-NMe2 
(Ph-O)2-P(= O)-NH-Me 
2x lo4 17 0 20 
2x IO4 0 0 20 
5x lOA 0 0 25 
5x10” 5 0 15 
1O-3 30 20 20 
5x104 10 0 IO 
1o-3 20 10 20 
IO4 20 10 < 5 
2x lo4 30 15 < 5 
10q 20 5 < 5 
2x lo+ 30 5 < 5 
4x lo4 0 0 0 
2x loq 0 0 0 
2 x lo-3 35 0 0 
4x lo4 25 0 10 
2x lo4 5 0 0 
2x lo+ 45 30 0 
4x lo4 70 33 0 
1o-3 80 35 0 
1o-5 > 95 30 0 
2x lo-5 > 95 55 15 
5 x 1o-s 65 0 0 
IO4 65 0 0 
1.5 x lo4 90 0 5 
lo-5 80 < 5 < 10 
2x 1o-5 >95 10 < 10 
4 x lo-s > 95 20 < 10 
1o-5 > 95 25 0 
2x 1o-5 > 95 30 0 
2x 1o-5 > 95 > 65 40 
5 x 1o-5 > 95 > 65 50 
4 x 1o-5 > 95 30 5 
lo4 > 95 40 < 10 
lo-s 50 0 0 
2x 1o-5 60 0 0 
2x lo4 > 95 0 0 
4x lo4 >95 0 < 10 
1O-3 > 95 40 10 
2x lo4 15 0 0 
5 x lo4 20 0 0 
5x IO4 70 20 20 
lO-3 8.5 40 25 
2x IO4 35 0 0 
5x lo4 40 0 0 
lo4 15 < 5 < 5 
2x lo4 10 < 5 < 5 
2x lo4 0 0 0 
5 x lo4 10 0 0 
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Table 2 
No. structure Molar 
concentration II, 
Inhibition (%) of factor 
V VII, VIII IX, X, 
21 (Cl-Ph-0)2-P(= O)-NHCH3 
19 @N02-Ph-O-)2-P(= OkNH-CH3 
11 m(Me,-CH(CH3)). Ph-O-Cc= OjNHCH3 
26 CH ,-Ph-O-U= O)-NHCH3 
16 @N02-Ph-0)2-JY= OFeth 
1 pCI-Ph-0-C(= O)-NH-Me 
2 Ph-0-Q’ O)-NH-Me 
17 @N02-Ph-0)2-P(= OkCH2-Ph 
27 CH 3-Ph-OC(= O)-NH-Ph 
lOA 0 0 0 0 
2x 1o-5 60 0 0 0 
2x IO4 5 0 20 0 
2x lo4 0 0 0 0 
2x 1o-5 95 0 40 0 
2x lOA 20 0 0 0 
1O-3 0 0 30 0 
4x lo+ 95 0 65 0 
4x IO4 30 0 45 0 
3 0 
10 0 
0 0 
20 20 
0 5 
0 20 
0 2s 
<5 50 
< 5 0 
Swart [ 111. A factor V preparation was obtained ac- 
cording to Kahn [ 191, factor VIII was prepared 
after Van Mourik et al. [ 121. 
The starting material for the preparation of 
thrombin was a concentrate of the factors II, VII, IX 
and X from plasma. This preparation was activated 
by addition of human brain thromboplastin (1% v/v) 
and dialysis against 12.5 mM CaC12 in 0.0 1 M Tris- 
HC1 buffer pH 7.0 at 4’ for 16 hr. This material was 
applied to a DEAE-Sephadex column in 0.01 M 
Tris-HCl buffer pH 7.0, and eluted stepwise with in- 
creasing concentrations of NaCl in the buffer. The 
fractions eluted between 0.05 M and 0.10 M con- 
tained a 9070 pure thrombin. The reference curve 
for the coagulation factor assays was obtained in 
dilutions of normal plasma at an acetone concen- 
tration of 0.5% (v/v). 
2.3. Assessment of’ the inhibition 
The inhibitors were dissolved in acetone. In all 
experiments and controls pure acetone was added 
so as to obtain a final concentration of 0.5% (v/v). 
The experiments were carried out as follows: At 
37” a sample of the coagulation factor preparation 
was incubated with the inhibitor at the desired con- 
centration. A blank was done in parallel. The de- 
crease in the blank was taken to represent nonspeci- 
fic inactivation (that is, denaturation of the coagu- 
lation factor). Coagulation factor determinations 
were carried out after 3 hr of incubation. 
In order to avoid misinterpretation of the results 
by an effect of the inhibitor on the coagulation 
factor assay, the coagulation time was determined 
immediately after addition of the inhibitor and 
after 3 hr of incubation, No, or only a marginal, 
i~ibition was observed at zero time. 
3. Experimental results 
In table I are given the results obtained with a 
series of 2.5 carbamates and phosphoric esters on 
coagulation factors II,, VII, and X,: None of these 
inhibited coagulation factors V(,) and VIII(,). Not 
all of these factors were tested on factor 1%. Table 2 
summarizes the effect of a selected group of inhibitor! 
on the factors II,, V, VII,, VIII, IX,, and X,. 
4. Discussion 
The fact that the four coagulation factors 11, VII, 
IX and X are inhibited by a series of compounds 
known to act on the active serine residue in esterases 
and proteolytic enzymes strongly argues in favour of 
their being serine esterases. The fact that these fac- 
tors are inhibited to a markedly different extent by 
different substances proves that they are individual 
moieties. As factors V and VIII are not inhibited, 
they probably are not serine esterases. 
The coagulation factor esterases have a remarkedly 
narrow specificity. Factors II, and X, can split tosyl- 
arginine methyl ester and benzoyl arginine methyl 
ester [3, 141 but the natural substrates of these en- 
zymes are other ~oaguIation factors. Factor II, 
(thrombin) acts on fibrinogen and factor XIII. Fac- 
tor VII, has only one proven action: conversion of th 
zymogen factor X in its active form (i.e. factor X,). 
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The same holds true for factor IX,. Factor X, in its 
turn can only act upon factor 11 to convert it into 
thrornbin. 
It has been shown that the factors VII,, IX, and 
X, as such cannot act on their natural substrates. 
Factors 1X, and X, need to be adsorbed onto a 
phospholipid surface (via a Ca-ion). Next to the 
factor acting as an esterase, another factor has to be 
adsorbed: factor V together with Xa; factor VIII 
with factor IX, [ 14- 171. The factors V and VIII 
could not be shown to have enzymatic properties 
[ 18, lo] . With factor VII the situation is less clear, 
it has been proven, however, that for its action a 
protein intimately bound to a lipid structure is 
necessary, both of which are derived from wounded 
cells [20] . 
It thus appears that the moieties active in blood 
coagulation consist of a serine esterase, adsorbed 
on a surface next to a protein (tentatively called 
paraenzyme [Z I] ) that in itself is inactive, but which 
determines the specificity of the esterase. 
For the mode of action of the paraenzyme two 
possibilities can be put forward: 
a) it causes changes in the tertiary structure of the 
esterase, so as to alter its specificity 
b) it provides accessory binding sites for the substrate 
so as to ensure matching of the vuInerable site on 
the substrate to the active site of the esterase. 
This problem is at present under investigation. 
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